Index of drugs

Treatment of the following infections in adults and children> 3 months of age: pneumonia (including community-acquired and nosocomial pneumonia); lung infections and bronchitis in the course of cystic fibrosis; complicated urinary tract infections; complicated intra-abdominal infections; perinatal infections; complicated skin and soft tissue infections; acute bacterial meningitis. It can be used to treat patients with neutropenia and fever, if fever is suspected to be caused by a bacterial infection. The official guidelines for the correct use of antibacterial drugs should be taken into account.

1 vial contains 500 mg or 1 g of meropenem (as a trihydrate); The medicine contains sodium, respectively: 1.95 mmol (45 mg) or 3.9 mmol (90 mg) of sodium in 1 vial.

Hypersensitivity to the components of the preparation and to any antimicrobial agent from the carbapenem group. Severe hypersensitivity (eg anaphylactic reaction, severe skin reaction) to any other anti-bacterial β-lactam medicine (eg penicillin or cephalosporins).

Avoid using meropenem during pregnancy. It is not known whether meropenem passes into breast milk. Taking into account the benefits of therapy for the mother, a decision should be made whether to discontinue breast-feeding or to stop taking meropenem or not to take it.

Common: thrombocytemia, headache, diarrhea, vomiting, nausea, abdominal pain, increased transaminases, increased alkaline phosphatase in the blood, increased LDH activity, rash, pruritus, inflammation, and pain. Uncommon: oral and vaginal yeast, eosinophilia, thrombocytopenia, leukopenia, neutropenia, paresthesia, increased bilirubin in the blood, urticaria, increased blood creatinine or urea, thrombophlebitis. Rare: convulsions. Not known: agranulocytosis, haemolytic anemia, angioneurotic edema, anaphylaxis, antibiotic associated colitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, injection site pain.

Intravenously.Adults and adolescents. Pneumonia (including community-acquired and nosocomial pneumonia), complicated urinary tract infections, complicated intra-abdominal infections, perinatal infections, complicated skin and soft tissue infections: 500 mg or 1 g every 8 hours. Cystic and bronchitis infections in cystic fibrosis , acute bacterial meningitis: 2 g every 8 h. Treatment of patients with neutropenia and fever: 1 g every 8 h. For the treatment of certain types of infections, such as hospital infections caused byPseudomonas aeruginosa orAcinetobacter spp, it may be advisable to use a dose of up to 2 g 3 times a day.Children from 3 months to 11 years old, about up to 50 kg. Pneumonia (including community-acquired and nosocomial pneumonia), complicated urinary tract infections, complicated intra-abdominal infections, complicated skin and soft tissue infections: 10 or 20 mg / kg. every 8 hours. Cystic and bronchitis infections with CF, acute bacterial meningitis: 40 mg / kg every 8 hours. Treatment of children with neutropenia and fever: 20 mg / kg every 8 hours. For the treatment of certain types of infections, such as hospital-acquired infectionsPseudomonas aeruginosa orAcinetobacter sppIn particular, a dose of up to 40 mg / kg may be recommended. 3 times a day. For children weighing> 50 kg, give the dose as for an adult. The safety and efficacy of meropenem have not been established in children <3 months of age and no optimal dosing regimen has been established for them; however, limited pharmacokinetic data indicate that the appropriate dosing regimen may be the administration of 20 mg / kg meropenem. every 8 hours.Special flu patients. In adults and adolescents with impaired renal function, the dose should be adjusted taking into account the creatinine clearance (CCr) - CCr 26-50 ml / min: 1 unit dose (depending on the indication) every 12 hours; CCr 10-25 ml / min: 1/2 unit dose every 12 hours; CCr <10 ml / min: 1/2 unit dose every 24 h. Data confirming this modification for a unit dose of 2 g are limited. In patients undergoing hemodialysis or haemofiltration, the appropriate dose should be administered after completion of hemodialysis. Dosing recommendations have not been established in patients undergoing peritoneal dialysis. There is no experience regarding the use of meropenem in children with impaired renal function. In patients with hepatic and elderly dysfunction, no dosage adjustment is necessary.Way of giving. The drug is usually administered as an intravenous infusion over approximately 15-30 minutes. Alternatively, doses up to 1 g in adults and adolescents or up to 20 mg / kg in children, it can be given by intravenous injection, lasting about 5 minutes. Limited data are available to confirm the safety of adult dosing of 2 g and children at 40 mg / kg. by intravenous injection.